Nerlynx

Puma Biotechnology Inc (NASDAQ: PBYI) shares advanced in premarket trading Wednesday on the back of an announcement concerning its breast cancer drug Nerlynx before falling after the market open.  What Happened The actively traded, small-cap biotech said after the close Tuesday that the FDA...

Shares of small-cap oncology biotech Puma Biotechnology Inc (NASDAQ: PBYI) are sinking to their lowest level since November following the release of its first-quarter results. Nerlynx Numbers Disappoint While Puma beat consensus earnings and revenue estimates, it appears to be an update on...

Puma Biotechnology Inc (NASDAQ: PBYI) announced fourth-quarter results and 2019 guidance Thursday that were ahead of expectations, boosting confidence in Nerlynx achieving a global product revenue estimate of $683 million in 2023, according to Cantor Fitzgerald. The Analyst Cantor Fitzgerald...

Puma Biotechnology Inc (NASDAQ: PBYI) released positive top-line results for its lead drug candidate PB272, or Nerlynx, which is being evaluated for treating HER2+ metastatic breast cancer patients who have failed two or more prior lines of HER2+ directed treatments. Nerlynx along with capecitabine...

Puma Biotechnology Inc (NASDAQ: PBYI), a company focused on developing cancer drugs, is seeing its stock hurtle to its lowest level in about 2 1/2 years following the release of its third-quarter results, which incidentally came in ahead of expectations. What Happened Puma Biotech's Q3...

Shares of Puma Biotechnology Inc (NASDAQ: PBYI), a development stage biotech company focusing on cancer treatment, are down over 25 percent in pre-market trading. What You Need to Know Puma Biotech announced Tuesday afternoon the Committee for Medicinal Products for Human Use of the European...